Last updated: 02/04/2020 17:00:24
Belimumab 10mg/kg versus Placebo Post-hoc Analysis of Corticosteroid Use across 52 Weeks of Treament (BLISS-52 & BLISS-76 Meta-analysis)
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: Belimumab 10mg/kg versus Placebo Post-hoc Analysis of Corticosteroid Use across 52 Weeks of Treament (BLISS-52 & BLISS-76 Meta-analysis)
Trial description: Previous belimumab analyses have been conducted to evaluate corticosteroid use in BLISS 52 & BLISS 76 (pivotal studies); however to date analyses have mostly focused on corticosteroid changes observed at Week 52. Further pooled post-hoc (BLISS 52 & BLISS 76) analyses were thus undertaken to evaluate changes in cumulative corticosteroid doses observed throughout the BLISS studies.
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Net cumulative change from baseline in prednisone dose
Timeframe: Day 0 to Day 364
Secondary outcomes:
Cumulative decrease in prednisone dose
Timeframe: Day 0 to Day 364
Change from baseline in average daily prednisone dose
Timeframe: Day 0 to Day 364
Cumulative increase in prednisone dose
Timeframe: Day 0 to Day 364
Interventions:
Enrollment:
0
Primary completion date:
2015-10-01
Observational study model:
Other
Time perspective:
Retrospective
Clinical publications:
van Vollenhoven R, Petri M, Wallace D, Roth D, Molta C, Hammer A, Tang Y, Thompson A . Cumulative Corticosteroid Dose Over Fifty-Two Weeks in Patients With Systemic Lupus Erythematosus: Pooled Analyses From the Phase III Belimumab Trials. Arthritis Rheum. 2016;68(9):2184-2192.
Medical condition
Systemic Lupus Erythematosus
Product
belimumab
Collaborators
Not applicable
Study date(s)
December 2013 to January 2015
Type
Observational
Phase
Not applicable
Participation criteria
Sex
Female & Male
Age
18+ years
Accepts healthy volunteers
none
- N/A
- N/A
Inclusion and exclusion criteria
Inclusion criteria:
- N/A
Exclusion criteria:
- N/A
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
Protocol
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Refer to study documents
Recruitment status
Study complete
Actual primary completion date
2015-10-01
Actual study completion date
2015-10-01
Plain language summaries
Not applicable. GSK’s transparency policy provides for Plain Language Summaries for Interventional studies.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website